Cargando…
An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents
Liver fibrosis represents a response to chronic liver injury. Metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatohepatitis are the most common chronic liver diseases, both with increasing incidence. Therefore, there is a great impetus for development of a...
Autores principales: | Rupcic Rubin, Vinka, Bojanic, Kristina, Smolic, Martina, Rubin, Jurica, Tabll, Ashraf, Smolic, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868700/ https://www.ncbi.nlm.nih.gov/pubmed/33604256 http://dx.doi.org/10.14218/JCTH.2020.00040 |
Ejemplares similares
-
Noninvasive Fibrosis Assessment in Chronic Hepatitis C Infection: An Update
por: Bojanic, Kristina, et al.
Publicado: (2023) -
Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
por: Kishta, Sara, et al.
Publicado: (2020) -
Therapeutic Perspectives of IL1 Family Members in Liver Diseases: An Update
por: Ćurčić, Ines Bilić, et al.
Publicado: (2022) -
MicroRNAs: Small Molecules with Significant Functions, Particularly in the Context of Viral Hepatitis B and C Infection
por: Megahed, Fayed, et al.
Publicado: (2023) -
Update on the Development of Anti-Viral Agents Against Hepatitis C
por: Macarthur, Kristin L., et al.
Publicado: (2013)